Cargando…

The application of histone deacetylases inhibitors in glioblastoma

The epigenetic abnormality is generally accepted as the key to cancer initiation. Epigenetics that ensure the somatic inheritance of differentiated state is defined as a crucial factor influencing malignant phenotype without altering genotype. Histone modification is one such alteration playing an e...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Rui, Zhang, Mengxian, Zhou, Yangmei, Guo, Wenjing, Yi, Ming, Zhang, Ziyan, Ding, Yanpeng, Wang, Yali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368699/
https://www.ncbi.nlm.nih.gov/pubmed/32682428
http://dx.doi.org/10.1186/s13046-020-01643-6
_version_ 1783560647230881792
author Chen, Rui
Zhang, Mengxian
Zhou, Yangmei
Guo, Wenjing
Yi, Ming
Zhang, Ziyan
Ding, Yanpeng
Wang, Yali
author_facet Chen, Rui
Zhang, Mengxian
Zhou, Yangmei
Guo, Wenjing
Yi, Ming
Zhang, Ziyan
Ding, Yanpeng
Wang, Yali
author_sort Chen, Rui
collection PubMed
description The epigenetic abnormality is generally accepted as the key to cancer initiation. Epigenetics that ensure the somatic inheritance of differentiated state is defined as a crucial factor influencing malignant phenotype without altering genotype. Histone modification is one such alteration playing an essential role in tumor formation, progression, and resistance to treatment. Notably, changes in histone acetylation have been strongly linked to gene expression, cell cycle, and carcinogenesis. The balance of two types of enzyme, histone acetyltransferases (HATs) and histone deacetylases (HDACs), determines the stage of histone acetylation and then the architecture of chromatin. Changes in chromatin structure result in transcriptional dysregulation of genes that are involved in cell-cycle progression, differentiation, apoptosis, and so on. Recently, HDAC inhibitors (HDACis) are identified as novel agents to keep this balance, leading to numerous researches on it for more effective strategies against cancers, including glioblastoma (GBM). This review elaborated influences on gene expression and tumorigenesis by acetylation and the antitumor mechanism of HDACis. Besdes, we outlined the preclinical and clinical advancement of HDACis in GBM as monotherapies and combination therapies.
format Online
Article
Text
id pubmed-7368699
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73686992020-07-20 The application of histone deacetylases inhibitors in glioblastoma Chen, Rui Zhang, Mengxian Zhou, Yangmei Guo, Wenjing Yi, Ming Zhang, Ziyan Ding, Yanpeng Wang, Yali J Exp Clin Cancer Res Review The epigenetic abnormality is generally accepted as the key to cancer initiation. Epigenetics that ensure the somatic inheritance of differentiated state is defined as a crucial factor influencing malignant phenotype without altering genotype. Histone modification is one such alteration playing an essential role in tumor formation, progression, and resistance to treatment. Notably, changes in histone acetylation have been strongly linked to gene expression, cell cycle, and carcinogenesis. The balance of two types of enzyme, histone acetyltransferases (HATs) and histone deacetylases (HDACs), determines the stage of histone acetylation and then the architecture of chromatin. Changes in chromatin structure result in transcriptional dysregulation of genes that are involved in cell-cycle progression, differentiation, apoptosis, and so on. Recently, HDAC inhibitors (HDACis) are identified as novel agents to keep this balance, leading to numerous researches on it for more effective strategies against cancers, including glioblastoma (GBM). This review elaborated influences on gene expression and tumorigenesis by acetylation and the antitumor mechanism of HDACis. Besdes, we outlined the preclinical and clinical advancement of HDACis in GBM as monotherapies and combination therapies. BioMed Central 2020-07-18 /pmc/articles/PMC7368699/ /pubmed/32682428 http://dx.doi.org/10.1186/s13046-020-01643-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Chen, Rui
Zhang, Mengxian
Zhou, Yangmei
Guo, Wenjing
Yi, Ming
Zhang, Ziyan
Ding, Yanpeng
Wang, Yali
The application of histone deacetylases inhibitors in glioblastoma
title The application of histone deacetylases inhibitors in glioblastoma
title_full The application of histone deacetylases inhibitors in glioblastoma
title_fullStr The application of histone deacetylases inhibitors in glioblastoma
title_full_unstemmed The application of histone deacetylases inhibitors in glioblastoma
title_short The application of histone deacetylases inhibitors in glioblastoma
title_sort application of histone deacetylases inhibitors in glioblastoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368699/
https://www.ncbi.nlm.nih.gov/pubmed/32682428
http://dx.doi.org/10.1186/s13046-020-01643-6
work_keys_str_mv AT chenrui theapplicationofhistonedeacetylasesinhibitorsinglioblastoma
AT zhangmengxian theapplicationofhistonedeacetylasesinhibitorsinglioblastoma
AT zhouyangmei theapplicationofhistonedeacetylasesinhibitorsinglioblastoma
AT guowenjing theapplicationofhistonedeacetylasesinhibitorsinglioblastoma
AT yiming theapplicationofhistonedeacetylasesinhibitorsinglioblastoma
AT zhangziyan theapplicationofhistonedeacetylasesinhibitorsinglioblastoma
AT dingyanpeng theapplicationofhistonedeacetylasesinhibitorsinglioblastoma
AT wangyali theapplicationofhistonedeacetylasesinhibitorsinglioblastoma
AT chenrui applicationofhistonedeacetylasesinhibitorsinglioblastoma
AT zhangmengxian applicationofhistonedeacetylasesinhibitorsinglioblastoma
AT zhouyangmei applicationofhistonedeacetylasesinhibitorsinglioblastoma
AT guowenjing applicationofhistonedeacetylasesinhibitorsinglioblastoma
AT yiming applicationofhistonedeacetylasesinhibitorsinglioblastoma
AT zhangziyan applicationofhistonedeacetylasesinhibitorsinglioblastoma
AT dingyanpeng applicationofhistonedeacetylasesinhibitorsinglioblastoma
AT wangyali applicationofhistonedeacetylasesinhibitorsinglioblastoma